<Anchor> An
application for emergency use of the corona vaccine developed by Johnson & Johnson, an American pharmaceutical company, has been received by the European Union.
The European Medicines Agency plans to hurry up the schedule and announce approval by next month.
This is reporter Kim A-young.
<Reporter> The
European Medicines Agency announced that it has received an application for emergency use of the Corona 19 vaccine developed by Johnson & Johnson, an American pharmaceutical company.
They then announced that they would proceed with the evaluation process faster than the usual schedule.
He explained that some of the data on efficacy and safety were reviewed in the phased review process, and that approval could be announced as early as mid-next month.
The European Union previously approved the emergency use of Pfizer, Modena and AstraZeneca vaccines.
Unlike the three types of vaccines that were previously approved by the EU, the Johnson & Johnson vaccine has the advantage that it only needs to be given once, but the EU has already secured 400 million doses of Johnson & Johnson vaccine.
Regarding the COVID-19 mutant virus, Russian health officials have announced that two vaccines developed in-house have also been effective in mutations originating in the UK.
When we verified the self-developed Sputnik V and Ebbac corona vaccines, it effectively neutralized the mutation from the UK, and it seemed to have waited immediately after President Putin's order to prepare a mutant virus response plan.
Meanwhile, Japan approved the Pfizer vaccine for the first time on the 14th, and will start vaccination for 40,000 healthcare workers starting today (17th).